Category Archives: Biology

Chili peppers more deeply rooted in Colorado than previously thought – University of Colorado Boulder

Banner image: Abel Campos, majoring in Ecology & Evolutionary Biology, examines a fossil in the Invertebrate Paleontology department at the University of Colorado Museum of Natural History. (Photo:Casey A. Cass / CU Boulder)

Botanists and paleontologists, led by researchers fromCU Boulder, have identified a fossil chili pepper that may rewrite the geography and evolutionary timeline of the tomato plant family.

The teams findings, published last month in the journal New Phytologist, show that the chili pepper tribe (Capsiceae) within the tomato, or nightshade (Solanaceae), family is much older and was much more widespread than previously thought. Scientists previously believed that chili peppers evolved in South America at most 15 million years ago, but new research pushes that date to at least 50 million years agoand suggests that chili peppers were in fact present in North America at that time.

Roco Deanna, a postdoctoral researcher in ecology and evolutionary biology, examines a chili pepper fossil that is at least 40 million years old. (Credit: R. Deanna)

Roco Deanna, a postdoctoral researcher in ecology and evolutionary biology, and Abel Campos, an undergraduate double majoring in evolutionary biology and molecular, cellular and developmental biology, weren't planning to rewrite history when they met up one afternoon at the CU Boulder Museum of Natural History in 2021. Yet among a group of specimens in its collections gathered from the Green River Formationgeological treasure trove in northwestern Colorado and southwestern WyomingDeanna spotted a specific, solanaceous trait embedded in one fossil: little spikes on the end of a fruiting stem.

At first, I thought No way! This cant be true, said Deanna, lead author of the study. But it was so characteristic of the chili pepper.

After they discovered two of these fossils in the CU Boulder collections, Deanna and Campos, a co-author of the study, found one more from the chili pepper tribe in collections at the Denver Museum of Nature and Science (DMNS). All three fossils are from the Green River Formation in Colorado: the CU specimens from Garfield County and the DMNS fossil from Rio Blanco County.

These chili pepper fossils from the Eocene geological epoch (34 to 56 million years ago) match the timeline of another nightshade fossil found in the Esmeraldas Formation in Colombia, revealing that the family was already distributed across all of the Americas by as early as 50 million years ago.

The family is way older than we thought, said Deanna, also a faculty member at the National University of Cordoba.

Talia Karim, Collection Manager for Invertebrate Paleontology at the University of Colorado Museum of Natural History, works with Abel Campos, majoring in Ecology & Evolutionary Biology with the museums fossil collection. (Credit: Casey A. Cass / CU Boulder)

The nightshade family comprises 3,000 species and almost 100 different genera, including chili peppers. The ancient chili pepper was technically a fruitand a berry, at that. While tomatoes and peppers are commonly associated with vegetables, they have seeds on the inside, which officially categorizes them as fruits.

The researchers cannot be sure of the chilis exact shape or color, but it was probably on the smaller end compared to modern day chili peppers. And like its relatives, it could have been quite spicy, according to Deanna.

Deanna and Campos identified the fossil by the unique shape of its calyx teeth: spikes on the end of the fruiting stem that hold on to the pepper, like those which hold a gemstone in a ring.

The world has maybe 300,000 plant species. The only plants with that kind of calyx is this group of 80 or 90 species, said Stacey Smith, senior author of the paper and associate professor of evolutionary biology at CU Boulder.

Paleontologists collected the CU Boulder fossil from the Green River Formation in the 1990s. But its exact identity remained a mystery for years, in part because there are only a handful of solanologists, botanists who study the nightshade family, in the world. When Deanna found these Colorado-based fossils, she had just returned from a global search for tomato family fossil specimens, only to find some just ripe for the picking right on campus.

A lot of discoveries happen decades after the specimens have been collected, said Smith. Who knows how many other new fossil species are sitting in any of these museums? They're just waiting for the right eyes to look at them.

Deanna and Campos identified this chili pepperfossil in theCU Boulder Museum of Natural History collectionsby the unique shape of its calyx teeth: spikes on the end of the fruiting stem that hold on to the pepper. (Credit:R. Deanna)

These chili pepper fossils were around during the Eocene, a geologic epoch that lasted from about 34 to 56 million years ago as the continents drifted toward their present positions. During this balmy time in Earths history, carbon dioxide levels ranged between 700 and 900 parts per million (twice as high as they are today), and palm trees grew as far north as Alaska. Because little to no ice was present on Earth, sea level was as much as 500 feet higher than it is today.

Top: The first chili pepper fossil identified by the researchers atthe CU Boulder Natural HistoryMuseum, shown next to aportion of measuring tape.(Credit:R. Deanna) Bottom: Another chili pepper fossil from the CU Bouldercollections.(Credit:S. Manchester)

Scientists had assumed that the origins of chili peppers began in South America roughly 10 to 15 million years ago, where they then dispersed over land and water to the other continents. While Colorado today is home to very few native nightshades and no chili peppers, this new discovery hints that a plethora of plants from the tomato plant family may have existed in North America 40 to 50 million years ago, which have since largely disappeared.

But how did these peppers first get to North America? Its now a case of the chicken or the chili pepper?

Experts have theorized that fruit-eating birds, which existed as early as 60 million years ago, may have carried seeds and plants around the world with them in their guts, stuck to their feathers or in the mud on their feet. But these birds also had to be eating something to fuel their journeysand fleshy berries, or peppers, make the perfect fuel. Birds may have distributed peppers from continent to continent, but peppers may also have been crucial to the success of those same birds.

So the nightshade family could have easily started in North America instead of South America, then dispersed in the other directionand with this discovery, scientists can no longer say for sure, said Smith.

These chili peppers, a species that we thought arose in an evolutionary blink of an eye, have been around for a super long time, said Smith. We're still coming to grips with this new timeline.

Additional authors on this publication include: Camila Martnez, Universidad EAFIT and Smithsonian Tropical Research Institute; Steven Manchester, Florida Museum of Natural History, University of Florida; Peter Wilf, Pennsylvania State University; Sandra Knapp, Natural History Museum, London; Franco E. Chiarini, Gloria E. Barboza, and Gabriel Bernardello of the Instituto Multidisciplinario de Biologia Vegetal, IMBIV (CONICET-UNC); Herve Sauquet, National Herbarium of New South Wales and Evolution and Ecology Research Centre, University of New South Wales; Ellen Dean, Center for Plant Diversity, University of California; Andres Orejuela, Grupo de Investigacion en Recursos Naturales Amazonicos GRAM, Facultad de Ingenieras y Ciencias Basicas, Instituto Tecnol ogico del Putumayo, and Subdireccion cientfica, Jardn Botanico de Bogota Jose Celestino Mutis.

Read more:

Chili peppers more deeply rooted in Colorado than previously thought - University of Colorado Boulder

Bryan Manzano selected as Eberly College of Science spring 2023 … – Pennsylvania State University

Bryan Manzano of Glen Mills, Pennsylvania, will be honored as the student marshal for the Penn State Eberly College of Science during the Universitys spring commencement ceremonies on Sunday, May 7, on the University Park campus. His escort for the commencement exercises is Cornelia Osbourne, graduate student in biology.

Manzano will graduate with a 4.0 grade-point average and bachelors degrees in biology and music performance. He is a Schreyer Scholar in the Schreyer Honors College and has been a member of the deans list every semester. Manzano was honored with an Evan Pugh Scholar Award in 2022 and a School of Music Scholarship in 2019. He also will be recognized as the student marshal for the Penn State College of Art of Architecture.

I am extremely humbled to be selected for this honor and am happy that my hard work as a double major has paid off, he said.

While at Penn State, Manzano conducted research with Illiana Baums, then a professor of biology, as well as Osbourne. He used the hybrid coral species Acropora prolifera to study the mismatch that can occur between the genome in the nucleus of a cell and the separate genome within mitochondria in the cell, called mitonuclear conflict. He wrote a literature review about the effects of this conflict on the second-generation offspring of these coral hybrids. He later developed computer code using a gene coexpression network analysis approach to compare the genome of the coral hybrid to that of its two parental species to look for evidence of mitonuclear conflict, which could impact future offspring viability. Manzano also worked with the lab to carry out a protocol to extract genetic material called RNA from the tissues of various species of corals.

In addition to his research activities, Manzano served as a teaching assistant for the course BIOL 220W: Ecology and Evolution. He was also the president of the School of Musics Encore Benefiting THON organization as well as a member of the Penn State Horn Society, the Penn State Symphonic Wind Ensemble, and the Penn State Philharmonic Orchestra. Manzano also performed as a part of the Nittany Valley Symphony and the Pennsylvania Chamber Orchestra.

I think my most important experience was going to Carnegie Hall as part of the presidents concert for the Symphonic Wind Ensemble in March 2020, he said. It taught me that when one studies at university, it is important to be able to take advantage of any travel experience you can in order to make memories that you will never forget.

After graduation, Manzano plans to work as a research technician in the lab of Song Tan, Verne M. Willaman Professor of Molecular Biology. He is excited to join this lab and help them work towards gaining further understanding of gene regulation, which could have implications for the development of future cancer treatments.

A graduate of Garnet Valley High School in Glen Mills, Pennsylvania, Manzano will be accompanied at commencement by his father, Patrick; sister, Alyssa; and partner, Carson Bechdel.

Read the original:

Bryan Manzano selected as Eberly College of Science spring 2023 ... - Pennsylvania State University

Biological Age Is A New Sign Of Health What It Means – Refinery29 Australia

To know your biological age, a test like the ones from the brands mentioned prior is necessary. Its really hard to change what you can't measure, says Trinna Cuellar, PhD, vice president of biology and head of research and development at Tally Health. What we're giving people is a tool to be able to begin to assess how they are ageing. Its important to note that your biological age isnt final, either its a snapshot of how youre ageing at the specific time you took the test. And unlike your chronological age, your biological age can ebb and flow. For example, if I decided to adopt healthier habits such as prioritising better sleep, exercising more often, eating better, drinking less alcohol, etc and I re-took that same biological age test weeks or months later, its likely that my number would be lower.

Read more:

Biological Age Is A New Sign Of Health What It Means - Refinery29 Australia

Post-doc Research Fellow L1, School of Biology job with … – Times Higher Education

Applications are invited temporary post of a UCD Post-doctoral Research Fellow Level 1 within UCD School of Biology and Environmental Science / Earth Institute.

RecoBar is an European consortium funded by the EU through the SusCrop- ERA-NET programme. The project builds on a rich catalogue of barley germplasm, and uses a variety of approaches addressing the use of barley diversity in novel ways, building upon a solid foundation of genotypic, phenotypic and functional knowledge. RecoBar will expand our knowledge on barley Agrobiodiversity, improving barley adaptation to changing climates and promoting sustainable crop production.

This post-doctoral research position will be based at University College Dublin, in Dublin, Ireland, and the appointed person will have to focus on the molecular characterization of the microbes associated with the rhizosphere of different genotypes of barley under a range of different environmental conditions. The post holder will also contribute to data management for generating knowledge in a form accessible to the land user. This researcher will play a major role in the consortium, connecting the various datasets collected by the research groups. There will be resources to travel and network with partners across Europe, including Spain, Italy, and Finland.

The post-doctoral fellow will have excellent skills in molecular methods to profile microbial communities in soil and root using high throughput sequencing, especially amplicon sequencing of fungi and bacteria. They will have the bioinformatic skills to assemble sequencing data into ecological datasets and will have access to environmental and barley genotypic data to associate to the microbial data. Ideally, they will also have some background in plant phenotyping, either above or belowground (e.g. roots). The post-doctoral research fellow will be part of a team that will conduct field and glasshouse studies, and will have an opportunity to learn advanced modelling techniques in the field of network science. The fellow will also have the opportunity to collaborate with a number of project members across Europe, and independence.

Salary range: 42,033 - 48,427 per annum

Appointment on the above range will be dependent upon qualifications and experience.

Closing date: 17:00hrs (local Irish time) on 18th April 2023 .

Applications must be submitted by the closing date and time specified. Any applications which are still in progress at the closing time of 17:00hrs (Local Irish Time) on the specified closing date will be cancelled automatically by the system.

UCD are unable to accept late applications.

UCD do not require assistance from Recruitment Agencies. Any CV's submitted by Recruitment Agencies will be returned.

The PD1 position is intended for early stage researchers, either just after completion of a PhD or for someone entering a new area for the first time. If you have already completed your PD1 stage in UCD or will soon complete a PD1, or you are an external applicant whose total Postdoctoral experience, inclusive of the duration of the advertised post, would exceed 4 years, you should not apply and should refer to PD2 posts instead.

Prior to application, further information (including application procedure) should be obtained from the Work at UCD website: https://www.ucd.ie/workatucd/jobs/

More here:

Post-doc Research Fellow L1, School of Biology job with ... - Times Higher Education

‘Genome Sequencing’ & How Biology Is Connected To AI; Explains Tarun Khanna – Business Today

Catch Rahul Kanwal, News Director, India Today & AajTak in conversation with Tarun Khanna, Jorge Paulo Lemann Professor, Harvard Business School at The Business Todays Most Powerful Women In Business. Khanna talks about how new AI technology like ChatGPT will impact the corporate world. He also explains 'Genome Sequencing' and how biology is connected to data and AI.

Watch the full session here: https://youtu.be/kwWQAM5WsGg

See the original post here:

'Genome Sequencing' & How Biology Is Connected To AI; Explains Tarun Khanna - Business Today

Science Labs and Their Impact at Ivy Tech Muncie Journal – Muncie Journal

By Lesley DeVoss, Ivy Tech Community College

MUNCIE, IN The science labs at Ivy Tech Community College Muncie-Henry County impact the college across the Schools and Campuses statewide. The space, located in the lower level of the John and Janice Fisher Building at 345 South High Street, Muncie, IN 47305, is set up to run high-level chemistry and biology classes.

Organic chemistry, a class that holds interest for students wanting to go into pre-med has been one of the highlights of the 2023 spring semester. Students travel from across the state to take the course. Kylar Kavanaugh is one such student. She is currently a student in the Chemistry program at the Ivy Tech Lafayette campus. She travels to Muncie, a four hour round trip, for the organic chemistry class weekly.

I have been so impressed with the quality of education at Ivy Tech. When I first found out I had to make the two-hour drive to Muncie every week, I was dreading it, but at this point I look forward to coming to lab. I was blown away by the quality of the space, especially compared to the chemistry labs at other locations. I feel like my passion for chemistry is encouraged and it has reignited my excitement for learning, Kavanaugh said.

Campus administration made it a priority to provide safe and well-equipped laboratory spaces for students when the renovation to the Fisher Building was completed. Dr. Aaron Goodpaster, Department Chair for Life and Physical Sciences and Associate Professor in Chemistry was dedicated to upgrading the downtown labs to incorporate as many classes as possible. Through careful planning and expenditures, the science labs were outfitted with high tech and high-end chemistry equipment such as seven fume hoods, a gas chromatography instrument, refractometer, and rotary evaporator.

I am humbled that I was able to have a small part in bringing such great learning spaces and equipment to the Muncie-Henry County campus. I know this investment in the community will help foster student learning and engagement in the sciences for the next several decades, Goodpaster said.

Photo provided

Improvements were also made for the biology labs with high-end microscopes and an outdoor lab space that will aid biology students in completing their degree. Carly Lehman is a biology major with Ivy Tech Muncie-Henry County. She is graduating this May from Ivy Tech and plans to complete a bachelors degree in biology by 2025. She has been on the Ivy Tech Muncie-Henry County campus since it was located primarily on Cowan Road.

Lehman said, These new labs have completely changed my experience as a student. The old labs on Cowan Road got the job done but that was about it. They also didnt have nearly as much space or equipment and essentially no natural light. These new labs in the Fisher Building are amazing! There is so much more equipment and space. There were some labs we were unable to fulfill in person at the Cowan Road labs due to lack of equipment so we would have to find a different way to perform them. As a hands-on learner, I need as much of a tangible experience as possible. These new labs provide me with the experience I need to move through my degree at my best.

The science labs are not only used for biology and chemistry majors. Nursing, health sciences, and general studies students also use the lab space. Future educators who are enrolled in the Ivy Tech Transfer as a Junior Pathway use the labs as well. Individuals interested in teaching in the chemistry or biology fields are afforded a high-tech education in the labs before completing their degree and transferring to a four-year partner as a junior.

Secondary Education students take their first two years toward a teaching degree with Ivy Tech, then transfer to a four-year university to complete their bachelors degree and any other requirements to become a licensed teacher, Dr. Sarah Haisley, Department Chair for Elementary and Special Education, said.

Students planning upon transferring to a 4-year university to study pre-med, education majors specializing in biology or chemistry, health science majors requiring a safe lab space to perform dissections, or general studies students planning on transferring to a 4-year university all use these labs to conduct experiments in a well-lit, ventilated space where they can safely learn. Many of these students remain locally, taking positions in quality control, education, and other careers where science provides a firm foundation for the future.

To learn more about the science labs at the Ivy Tech Muncie-Henry County campus send an email to askmuncie@ivytech.edu. Apply to Ivy Tech by visiting ivytech.edu/apply-now.

About Ivy Tech Community College

Ivy Tech Community College is Indianas largest public postsecondary institution and the nations largest singly accredited statewide community college system, accredited by the Higher Learning Commission. Ivy Tech has campuses throughout Indiana and serves thousands of students annually online. It serves as the states engine of workforce development, offering associate degrees, short-term certificate programs, industry certifications, and training that aligns to the needs of the community. The College provides seamless transfer to other colleges and universities in Indiana, as well as out of state, for a more affordable route to a bachelors degree. Follow Ivy Tech on Facebook, Twitter, Instagram, and LinkedIn for the most up-to-date information.

See more here:

Science Labs and Their Impact at Ivy Tech Muncie Journal - Muncie Journal

Real AI Will Need Biology: Computers Powered by Human Brain Cells – Neuroscience News

Summary: The human brain continues to massively outperform AI technology in a range of tasks, a new study reports. Researchers outline their plans for biocomputers and organoid intelligence systems as future improvements for artificial intelligence technology.

Source: Cortical Labs

The time has come to create a new kind of computer, say researchers from John Hopkins University together with Dr Brett Kagan, chief scientist at Cortical Labs in Melbourne, who recently led development of theDishBrainproject, in which human cells in a petri dish learnt to play Pong.

In an article published today inFrontiers in Science, the team outlines how biological computers could surpass todays electronic computers for certain applications while using a small fraction of the electricity required by todays computers and server farms.

Theyre starting by making small clusters of 50,000 brain cells grown from stem cells and known as organoids. Thats about a third the size of a fruit fly brain. Theyre aiming for 10 million neurons which would be about the number of neurons in a tortoise brain. By comparison, the average human brain has more than 80 billion neurons.

The article highlights how the human brain continues to massively outperform machines for particular tasks. Humans, for example, can learn to distinguish two types of objects (such as a dog and a cat) using just a few samples, while AI algorithms need many thousands. And while AI beat the world champion in Go in 2016, it was trained on data from 160,000 games the equivalent of playing for five hours each day, for more than 175 years.

Brains are also more energy efficient. Our brains are thought to be able to store the equivalent of more than a million times the capacity of an average home computer (2.5 petabytes), using the equivalent of just a few watts of power. US data farms, by contrast, use more than 15,000 megawatts a year, much of it generated by dozens of coal-fired power stations.

In the paper, the authors outline their plan for organoid intelligence, or OI, with the brain organoids grown in cell-culture. Although brain organoids arent mini brains, they share key aspects of brain function and structure. Organoids would need to be dramatically expanded from around 50,000 cells currently.

For OI, we would need to increase this number to 10 million, says senior author Prof Thomas Hartung of Johns Hopkins University in Baltimore.

Brett and his colleagues at Cortical Labs have already demonstrated that biocomputers based on human brain cells are possible. A recent paper inNeuronshowed that a flat culture of brain cells could learn to play the video game Pong.

We have shown we can interact with living biological neurons in such a way that compels them to modify their activity, leading to something that resembles intelligence, says Kagan of the relatively simple Pong-playing DishBrain.

Working with the team of amazing people assembled by Professor Hartung and colleagues for this Organoid Intelligence collaboration, Cortical Labs is now trying to replicate that work with brain organoids.

I would say that replicating [Cortical Labs] experiment with organoids already fulfils the basic definition of OI, says Thomas.

From here on, its just a matter of building the community, the tools, and the technologies to realise OIs full potential, he said.

This new field of biocomputing promises unprecedented advances in computing speed, processing power, data efficiency, and storage capabilities all with lower energy needs, Brett says. The particularly exciting aspect of this collaboration is the open and collaborative spirit in which it was formed. Bringing these different experts together is not only vital to optimise for success but provides a critical touch point for industry collaboration.

And the technology could also enable scientists to better study personalised brain organoids developed from skin or small blood samples of patients suffering from neural disorders, such as Alzheimers disease, and run tests to investigate how genetic factors, medicines, and toxins influence these conditions.

Note: TH is named inventor on a patent by Johns Hopkins University on the production of brain organoids, which is licensed to AxoSim, New Orleans, LA, United States, and receives royalty shares.

TH and LS consult AxoSim. JS is named as inventor on a patent by the University of Luxembourg on the production of midbrain organoids, which is licensed to OrganoTherapeutics SARL, Esch-sur-Alzette, Luxembourg. JS is also co-founder and shareholder of OrganoTherapeutics SARL.

AM is a co-founder and has equity interest in TISMOO, a company dedicated to genetic analysis and human brain organogenesis, focusing on therapeutic applications customized for autism spectrum disorders and other neurological disorders with genetic origins.

The terms of this arrangement have been reviewed and approved by the University of California, San Diego, in accordance with its conflict of interest policies. BK is an inventor on patents for technology related to this paper along with being employed at and holding shares in Cortical Labs Pty Ltd, Melbourne, Australia.

No specific funding or other incentives were provided for involvement in this publication.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author: Press OfficeSource: Cortical LabsContact: Press Office Cortical LabsImage: The image is in the public domain

Original Research: The findings will appear in Frontiers in Science

Read more:

Real AI Will Need Biology: Computers Powered by Human Brain Cells - Neuroscience News

To save traditional Mohawk basketry, Akwesasne uses biology to outsmart the emerald ash borer – North Country Public Radio

Mar 06, 2023

When the emerald ash borer was first discovered in Akwesasne Mohawk territory in 2016, it was a painful blow. Not only are ash trees essential parts of the forest, but theyre also the raw material for the basket-making tradition thats at the heart of Mohawk culture.

Artists like Carrie Hill rely on ash trees as the primary material for their basketry. Hogansburg, NY. October 2019. Photo: Amy Feiereisel

So when scientists in Akwesasne took on how to stop the beetles from devouring all the ash trees, they started by observing how the insects kill a tree.

"They carve these very characteristic feeding galleries, which are like tunnels," said Jessica Raspitha,land resources program manager for the St. Regis Mohawk Tribes environment division. "Over time, that damage gets so excessive that it cuts off the vascular tissue, which prevents it from transporting the water nutrients through the tree, effectively killing it."

How Akwesasne Mohawks are using biology to stay ahead of the emerald ash borer

The Tribe recently got the third year of a nearly $650,000 U.S. Department of Agriculture grant to find innovative ways to keep the emerald ash borer population in check, mostly without using toxic pesticides.

Raspitha told David Sommerstein about a series of measures rooted in biology and silviculture designed to outsmart the EAB and keep the insects from destroying all the ash trees in Akwesasne. She started by describing one way, setting up what she calls trap trees.Their conversation has been lightly edited for clarity.

JESSICA RASPITHA: What that entailed was removing sections of the bark on the trunk, and that induces stress in the tree. The tree releases a certain type of pheromone that attracts the EAB, and at the end of the season, that tree would then be removed from the forest. We would strip the bark off of it to see how many EAB have come into that tree.

So this serves both as a population sink because the EAB was drawn to that particular tree rather than toward the healthy trees and it also allows us to evaluate the population.

DAVID SOMMERSTEIN:Wow. So you were actually attracting the emerald ash borer, like 'hey, come over to this tree. So we can kind of get a sense of what's going on, but also so that you won't go over to all those other trees.'

RASPITHA:Yes, that was the intent and how it works. What we did find was that the populations were growing, but we didn't find any old galleries. All the galleries that were there were new, which indicated that our detection methods were fairly early and that we were seeing an early infestation and not one that had been building for years.

Damage done to an ash tree by the emerald ash borer in Akwesasne. Photo: St. Regis Mohawk Tribe

SOMMERSTEIN: How widespread is the emerald ash borer in Akwesasne in the territory? What percent of ash trees are infected? Do we know that?

RASPITHA:I don't know that we know a specific percentage. We do know that since its first finding in 2016 in one of our green funnel traps, we've continued the funnel trap method every year since and we've seen it slowly spread from one corner of the reservation all the way through the territory. So we do know that it is everywhere. But the exact percentage of infestation is unknown.

So to speak to some of the other approaches we've used, some of them are a little more long-term than the population sinks. The population sinks are good for trying to prevent further spread in certain areas. But we also do silviculture work. So that's part of a long-term strategy.

In some of the state forests around Akwesasne, we have traditional rights within certain state forests. So those are customary use areas that we also try to protect as well as the trees within the tribal territory. Silviculture is a form of forest management. It includes the removal of some trees in order to prompt desired growth.

We are also doing some pesticide application. So we have been for the last three years now doing trunk injections on certain high-value ash trees. We're using an insecticide made out of emamectin benzoate. It's injected into the trunk of a tree, and what happens is that when the eggs of the EAB hatch, the larvae are not able to eat the vascular tissue because it will kill...

SOMMERSTEIN:Yeah, I've heard about that, that you can protect certain trees and inoculate them. How do you decide what's a 'high-value' ash tree?

RASPITHA: That's done both under the guidance of our tribal forester and also we have the great fortune of working with a sixth-generation basketmaker on our team. Our land resources technician has a really good eye for spotting what is a high-value tree in terms of basketry. They have a good eye at evaluating what is the high-value tree in terms of forest health.

But the limiting factor with the pesticide injection is that, for one, the insecticide itself is expensive. And for two, there's a lot of time that's required to evaluate whether a tree is a good candidate for injection or nor. But to date, we've injected 118 trees, so we're able to do about 50 a year.

The other drawback to it is that the insecticide only works for about three years. So we do need to revisit the site every couple of years to make sure that they're still healthy.

SOMMERSTEIN:So what does this all mean for the future of ash trees in Akwesasne? I mean, this is a problem across the North Country, certainly in the Adirondacks where there are huge amounts of ash trees, but in Akwesasne, it's an especially difficult problem because not only are they beautiful trees that are a huge part of the ecosystem, but they're also a huge part of the culture and people's livelihoods in making black ash baskets and basketry.

RASPITHA:So right now the trees are still in a steady decline. But one of the other long-term methods that we are starting to work with is facilitating the release of bio-control parasitoid wasps. So we are working with three different species. Two of them attack the EAB during the larval stage. One attacks the egg stage.

SOMMERSTEIN:Wow, certain kinds of wasps that attack the emerald ash borer?

RASPITHA:Yeah, so we've been working really closely with USDA to try to evaluate the sites, because you need to first find a thriving EAB population, so the wasp has something to eat. And once we've established that there is a sufficient population of EAB, we release the wasps, and then we revisit those sites every year to make sure that both the EAB populations are declining and that the wasp populations are sustaining.

I think the long-term goal, at least from my perspective, is that we will eventually reach a point where if our biocontrols are sustaining their populations, they will be able to keep the EAB populations in check. And so not so much that we're reaching toward eradication of the EAB but that their populations won't reach the point where they are killing our trees.

SOMMERSTEIN:Do you feel pressure because you're in charge of this thing, you're trying to maintain this huge Mohawk tradition?

RASPITHA:Some pressure, yes, because the ash tree is so important to the culture, and the cultural practice itself relies upon the availability of the resource. It's something that's been available to continue to practice for thousands of years, so there's a lot of fear that if our control efforts don't work, that it might not be there in the future, to sustain the actual cultural practices that go with it. But I also think it's important to acknowledge that while our current efforts have only been going on for the last three years, the work to preserve ash trees has been going on for decades.

Read more here:

To save traditional Mohawk basketry, Akwesasne uses biology to outsmart the emerald ash borer - North Country Public Radio

Do masks work? Its a question of physics, biology, and behavior – Ars Technica

Enlarge / Asian woman with protective face mask using smartphone while commuting in the urban bridge in city against crowd of people

On March 28, 2020, as COVID-19 cases began to shut down public life in much of the United States, then-Surgeon General Jerome Adams issued an advisory on Twitter: The general public should not wear masks. There is scant or conflicting evidence they benefit individual wearers in a meaningful way, he wrote.

Adams advice was in line with messages from other US officials and the World Health Organization. Days later, though, US public health leaders shifted course. Mask-wearing was soon a pandemic-control strategy worldwide, but whether this strategy succeeded is now a matter of heated debateparticularly after a major new analysis, released in January, seemed to conclude that masks remain an unproven strategy for curbing transmission of COVID-19 and other respiratory viruses.

Theres still no evidence that masks are effective during a pandemic, the studys lead author, physician, and epidemiologist Tom Jefferson, recently told an interviewer.

Many public health experts vigorously disagree with that claim, but the study has caught attention, in part, because of its pedigree: It was published by Cochrane, a not-for-profit that aims to bring rigorous scientific evidence more squarely into the practice of medicine. The groups highly regarded systematic reviews affect clinical practice worldwide. Its really our gold standard for evidence-based medicine, said Jeanne Noble, a physician and associate professor of emergency medicine at the University of California, San Francisco. One epidemiologist described Cochrane as the Bible.

The new review, Physical interventions to interrupt or reduce the spread of respiratory viruses, is an updated version of a paper published in the fall of 2020. It dropped at a time when debates over COVID-19 are still simmering among scientists, politicians, and the broader public.

For some, the Cochrane review provided vindication. Mask mandates were a bust, conservative columnist Bret Stephens wrote in The New York Times last week. Those skeptics who were furiously mocked as cranks and occasionally censored as misinformers for opposing mandates were right.

Meanwhile, masks continue to be recommended by the US Centers for Disease Control and Prevention, which describes them as a critical public health tool. And this winter, some school districts issued short-term mandates in an effort to curb not just COVID-19, but other respiratory viruses, including influenza and RSV.

The polarized debate conceals a murkier picture. Whether or not masks work is a multilayered questionone involving a mix of physics, infectious disease biology, and human behavior. Many scientists and physicians say the Cochrane reviews findings were, in a strict sense, correct: High-quality studies known as randomized controlled trials, or RCTs, dont typically show much benefit for mask wearers.

But whether that means masks dont work is a tougher questionone that has revealed sharp divisions among public health researchers.

The principle behind masks is straightforward: If viruses like SAR-CoV-2 or influenza can spread when droplets or larger particles travel from one persons nose and mouth into another persons nose and mouth, then putting up a barrier may slow the spread. And theres certainly evidence that surgical masks can block some relatively large respiratory droplets.

Early in the pandemic, though, some researchers saw evidence that SARS-CoV-2 was spreading via tinier particles, which can linger in the air and better slip around or through surgical and cloth masks. Sweeping mask recommendationsas many have proposedwill not reduce SARS-CoV-2 transmission, respiratory protection experts Lisa Brosseau and Margaret Sietsema wrote in an April 2020 article for the Center for Infectious Disease Research and Policy at the University of Minnesota.

Their colleague Michael Osterholm, a prominent epidemiologist, was more blunt: Never before in my 45-year career have I seen such a far-reaching public recommendation issued by any governmental agency without a single source of data or information to support it, he said on a podcast that June. (The Minnesota center receives funding from 3M, which manufactures both surgical masks and respirators.)

In a recent interview with Undark, Brosseau stressed that she thinks cloth and surgical masks have some protective benefit. But she and others, including Osterholm, have urged policymakers to emphasize tight-fitting respirators like N95s, rather than looser-fitting cloth and surgical masks. That's because theres clear evidence that respirators can effectively ensnare those tiny particles. A well-fitting, good quality respirator will trap the virus, almost all of it, and will greatly reduce your exposure to it, said Linsey Marr, an engineering professor at Virginia Tech who studies the airborne transmission of viruses.

When air flows through a respirator, it passes through a dense mesh of fibers. Those tiny particles collide with the fibers and get stuck, thanks to electrostatic forcesthe same force that makes hair stick to a balloon.

There is a huge reduction in the number of particles that get through, Marr said. (Indeed, the "95" in the N95 rating indicates that a mask, used properly and under the right conditions, is designed to capture roughly 95 percent of airborne particles.)

A popular online physics education channel offers an animated breakdown of how N95 masks work to reduce exposure to airborne particles.

In the laboratory, researchers can actually test out respirator performance. For one paper, published in 2020, scientists placed two mannequin heads in a translucent box. Using a nebulizer and actual SARS-CoV-2 virus, they piped a mist of virus suspension through the mouth of one mannequin, mimicking an exhaling person. They used a ventilator to draw air into the other mannequins mouth. Finally, they fitted the mannequins with various combinations of masks, respirators, or nothing at all, and tested how much of the virus evaded capture as it journeyed between the mannequins. Cloth and surgical masks did have an effect but were substantially outperformed by the N95s, which captured most of the viral particles.

Just because an N95 captures particles in the lab, however, doesnt necessarily mean it will stop an actual person from getting infected out in the world. Part of the issue is that people dont always wear respirators properly. And, even if the respirator performs well, the viral particles that slip through could be enough to make a person sick anyway. In the mannequin study, even an N95 taped snugly to a mannequins face failed to capture all the particles.

Enlarge / One 2020 study using mannequin heads found that cloth and surgical masks did have an effectbut were substantially outperformed by the N95s, which captured most of the viral particles.Over the past 15 years, a handful of research teams have tried to test out mask and respirator performance in the real world, through randomized controlled trials. Such studies are often considered the highest standard of evidence, because they can minimize sources of bias. In one such study, conducted in the winter of 2009 and 2010, the Australian epidemiologist Raina MacIntyre and several colleagues divided nearly 1,700 health care workers in Beijing into three groups. People in one group were told to wear surgical masks at work. Another group was instructed to wear an N95 at all times. And a third group was asked to wear an N95 only during certain high-risk procedures. Then, for four weeks, the team tracked how often the participants got sick.

MacIntyre and her colleagues reported that the people who wore N95s all day were significantly less likely to develop a respiratory illness than everyone else.

Other studies have produced mixed results. Some found that the masks or respirators had a small effect on someones odds of getting sick, but not always enough to be considered statistically significant. Others didnt find any benefit at all when comparing N95s to surgical masks, or even surgical masks to non-masking.

Do those findings apply, though, when millions of people are masking together, in the middle of a pandemic? At this scale, the question of whether or not masks work can be treated as a policy question: Did mask requirements actually reduce the spread of COVID-19? But doing a randomized controlled trial to answer this question is probably impossible, said Jing Huang, a biostatistician at the University of Pennsylvanias Perelman School of Medicine. Its not easy to just ask a few dozen randomly selected cities to implement mandates, and a few dozen to avoid mandates, and then track what happens.

And yet, this scenario did happen naturally during the COVID-19 pandemic: Some places put in mask mandates, and others did not. This sort of natural experiment opened up an opportunity for researchers to sift through health data in these different locations and try to suss out patternsand Huang and her colleagues recently did just that. They matched 351 counties in the United States that had implemented mask mandates with counties that did not have a mandate, but that were otherwise similar in several other respects. This means that, when possible, the COVID rates in a Republican-leaning, suburban county in the South that implemented a mask mandate during moderate COVID-19 spread would be measured against infection rates in another right-leaning, suburban Southern county that did not put a mandate into place at the same time.

Huang's analysis found that mask mandates were associated with substantially dampened COVID-19 spikes, although the benefit waned over time in some counties. The reason behind that waning was unclear, but could perhaps be could be due to fatigue with the mandates, the researchers suggested. Similar studies have oftenbut not alwaysfound a positive effect.

Whether the masks were responsible for those benefits, though, was hard to pin down, Huang said. Its possible that other factorssuch as other policies implemented alongside mask mandates, or greater social distancingactually kept COVID-19 rates lower, rather than the masks themselves. I think its very difficult, Huang said, to make a causation conclusion.

The CDC has cited other observational studies to justify its masking recommendation. One 2022 study found that people in California who chose to wear N95s were less likely to catch COVID-19 than people using other kinds of respiratory protection, who were themselves less likely to fall ill than people did not wear a mask at all. But the study was criticized for doing little to control for all the other ways people who wear N95s may behave differently than people who never wear masks. Was it the masks that made the difference? Or was it those other cautionary behaviors that people who tend to wear N95s also engage in that reduced their risk?

Cochranes methods were designed precisely to unravel these kinds of vexing medical questions. The organization was launched in 1993, with the mission, as reporter Daniel Kolitz wrote in a feature for Undark, of gathering and summarizing the strongest available evidence across virtually every field of medicine, with the aim of allowing clinicians to make informed choices about treatment."

Today, Cochrane maintains a network of thousands of affiliated researchers, who produce hundreds of reviews each year while working under the Cochrane banner. Those reviews tend to answer very specific questions: For example, does taking vitamin C reduce the incidence, the duration or severity of the common cold? Each team first searches the vast scientific literature, trying to amass an exhaustive list of relevant published and unpublished studies. Then, they select studies that meet Cochranes thresholds for rigor, and systematically organize and synthesize the data, aiming to produce a succinct answer to the original question.

Those reviews prioritize randomized controlled trialsthings like the experiment with the Beijing health care workersover other kinds of studies.

Tom Jefferson, who is an instructor in the Department for Continuing Education at the University of Oxford, is the first author on Cochrane's recent masking review. For nearly two decades, hes been part of a Cochrane team that examines the effects of certain interventions on the spread of respiratory viruses. The team has considered a range of questions: Do respirators help slow the spread of respiratory illnesses? Does handwashing? Does gargling?

Jeffersons group published its first systematic review of these kinds of questions in 2006. For the most recent, updated review, Jefferson and 11 collaborators synthesized evidence from 78 such RCTs, including 18 studies that specifically examined mask and respirator use. (They also looked at five ongoing studies, including two that look at mask use.) Their conclusion is principally about the absence of evidence: Taken together, they found, those studies simply do not offer evidence that asking people to wear an N95 instead of a surgical mask significantly reduces their odds of getting sick. Similarly, they did not find evidence that wearing surgical masks offered an advantage over wearing nothing at all.

Few of the studies took place during the COVID-19 pandemic, instead looking at infections during cold and flu seasons. And the majority of the studies only looked at whether masks and respirators protect the wearer from getting sick not whether they reduce the odds that a sick mask-wearer will infect other people.

Some researchers agree that randomized controlled trials dont currently show clear-cut evidence that masks and respirators reduce the wearers odds of getting sick. But, they argue, RCTs may not actually be the best source of evidence for determining whether masks confer protection. Strictly speaking, they're correct that there's no statistically significant effect, said Ben Cowling, an epidemiologist at the University of Hong Kong whose research is cited in the Cochrane review. But when you look at the totality of evidence, I think there's a pretty good indication that masks can protect people when they wear them.

In particular, Cowling said, mechanistic studieslike those conducted with mannequinsdo offer strong evidence that respirators cut down on the passage of viral particles.

Huang, the Penn biostatistician, is among others who argue that, in many RCTs examining mask use, the sample sizes are just too small. Even if masks are effective, that may not show up as a statistically meaningful result. When the effect is moderate, or small, we really need a large sample size to find a significant difference, said Huang. Many of these RCTs, she said, simply werent large enough to find some potentially meaningful signal.

And even if the effect is modest, during peak periods of a pandemic, small advantages can have a large impact by reducing the number of sick patients seeking hospital care at the same time. From a public health perspective," said Cowling, "reducing the reproductive number by even 10 percent could be valuable."

For a complex issue like masks, Trish Greenhalgh is among other researchers who suggest that an RCT may be an imperfect tool. I'm not against RCTs, said Greenhalgh, a physician and health researcher at the University of Oxford. But they were never designed to look at complex social interventions."

Greenhalgh is an influential figure in the evidence-based medicine movementher book How to Read a Paper: The Basics of Evidence-Based Medicine and Healthcare is in its sixth editionbut she has at times been critical of what she characterizes as an overreliance on RCTs. Greenhalgh characterized some of her colleagues as, in effect, RCT hardlinersfocused on RCTs at the expense of considering other kinds of evidence. In that mindset, she said, it seems that an RCT, however bad, is better than an observational study, however good."

Cochranes own leadership seems to share some of those concerns. In November 2020, when Jeffersons team published an earlier version of their review, Cochrane published an accompanying editorial, warning policymakers to move cautiously with the results, and not to interpret them as definitive evidence that masks and respirators dont work. Instead, the group wrote, there may never be strong evidence regarding the effectiveness of individual behavioral measures.

Some observers have suggested that such warnings are more about politics than science.

In an interview with the journalist Maryanne Demasi, Jefferson accused Cochrane of slow-walking an earlier version of the review, and of writing the editorial in order to undermine our work. (In an email sent to Undark via Harry Dayantis, a Cochrane spokesperson, the editor in chief of the Cochrane Library, Karla Soares-Weiser, said the processing time was standard for such a long review. "We wrote the editorial to help contextualize the review in the hope that it would help to prevent misinterpretations of the findings, she wrote. As we've seen from the response to the 2023 update, the risk of misinterpretation is very real!)

The review is not the first time that Jefferson has found himself challenging prevailing medical opinion. Years ago, he drew attention for arguing that the benefits of influenza vaccines had been overstated. (A 2009 article in The Atlantic described him as the most vocaland undoubtedly most vexingcritic of the gospel of flu vaccine, noting that he had become something of a pariah among flu researchers.) He has spent years arguing that the drug oseltamivir, also known as Tamiflu, and another antiviral medication may be less beneficial for influenza patients than drugmakers and public health authorities have claimed. More recently, he and another author on the Cochrane review, Canadian physician and World Health Organization adviser John Conly, have questioned the role of small airborne particles in transmitting SARS-CoV-2.

Jefferson has also done some writing for The Brownstone Institute. Founded by libertarian Jeffrey Tucker, the organization is broadly opposed to public health restrictions during the COVID-19 pandemic.

Jefferson declined to be interviewed for this article, sharing links to three Substack posts in which he criticizes press coverage of the COVID-19 pandemic. Most media are as complicit in spreading fear and panic as governments and their psyops people, he writes in one of the posts, going on to draw an analogy between reporters and Nazi functionaries.

Attempts to arrange interviews with four other authors of the Cochrane review, including Conly, were unsuccessful.

At times, the conversation about masks can verge on larger questions about human nature, and about how research should take into account the messiness of peoples behavior.

At issue is a contentious detail: In many of the RCTs analyzed in the Cochrane review, its not clear whether the people who were told to wear masks or respirators actually did so consistently and correctly. In addition, many such studies only ask people to wear respiratory protection for part of the day, meaning even if the mask or respirator works to stop infections when its on, the wearer may just get sick at other times. Marr, the Virginia Tech professor, compared this to a study that asks people to wear condoms only half the time they have sex: What do you thinks going to happen?"

Some people are skeptical that such distinctions really matter, at least when it comes to policymaking. Your policy has to exist in the real world. That's the thing, said Shira Doron, a physician and the chief infection control officer at Tufts Medicine. A respirator, used perfectly and continuously, may work to reduce the spread of COVID-19. But if theres a public health intervention that requires strict adherence, and almost nobody seems willing or able to follow it, is that actually an effective intervention at all? What does it even mean to say that it works?

Noble, the emergency physician, has led the UCSF Hospital emergency departments COVID-19 response. Perfect masking, she said, is out of reach for many people. In some casesshe brought up elderly patients who struggle to communicate when maskedit can even have harms. And masking policies, she said, dont always seem to recognize that reality, especially at a stage in the pandemic when vaccines are widely available. Her own work suggests that even fitted respirators, worn by health care workers, can swiftly lose their shape and fit, perhaps undercutting their protective benefits. "It's just harder to fit a human being than it is a mannequin, she said. And then we just cannot wear them correctly, for any length of time, because of the discomfort.

Doron spoke warmly about the Cochrane review, while stressing that it had limits. "This study has concluded, not that masks don't work, but that there is not evidence that masking on a population level decreases the incidence of infection. That's what it proves, she said. She still thinks a good, well-fitting respirator can help prevent someone from catching COVID-19. Why do I think that I think that? Because of the totality of evidence from non-RCTs that address that question. But do I know it? No, I do not.

It can be difficult to determine what all of this evidenceand gaps in evidencemean for mask mandates. Cowling spoke with Undark via Skype from Hong Kong, where officials continued to enforce a mask mandate until this week, issuing steep fines for people who did not cover up in public spaces, both indoors and outdoors.

Cowling, who heads the Department of Epidemiology and Biostatistics at the University of Hong Kongs School of Public Health, expressed doubts about that kind of policy. He argued that the evidence is clear that widespread masking, deployed during a pandemic surge, may help to flatten the curve and save lives. That's the exact scenario that public health measures are designed for, he said. But that's not the way they've been used in the last years, he added.

"What's happened in many parts of the world is that measures are brought in and kept in place, Cowling said, far longer than they're needed."

This article was originally published on Undark. Read the original article.

[/ars_image]

Go here to read the rest:

Do masks work? Its a question of physics, biology, and behavior - Ars Technica

Synthetic biology could disrupt some of the worlds biggest industries. Here are four steps to building a syn-bio strategy – Fortune

Three years ago, Frances Lesaffre, one of the worlds largest and oldest yeast manufacturers,entered into an alliancewith the Silicon Valley-based syn-bio startup Recombia Biosciences. While Lesaffre had usedyeast and yeast extracts to produce a range of products, from baking ingredients to flavors and biofuels, over the last decade, new syn-bio firms had begun modifying yeast, expanding the number of molecules obtainable through yeast fermentation. To stay at the forefront of innovation, Lesaffre decided to partner with Recombia in 2020and that partnership helped accelerate the development of yeasts to produce fermented ingredients.

With the startups proprietary technologies proving to be critical for its future,Lesaffreacquired Recombiain March 2022. Since then, it has incorporated Recombias genome editing technologies into itsbio-foundryto gain a head start in the biggest business opportunity of the century, namely synthetic biology. Thats no exaggeration; syn-bio applications are likely to disrupt industries that accounted for as much as a third of global output in 2022, according toBCGs recent studies.

Like Lesaffre, incumbents in many industries are experimenting with syn-bio strategies, but it isnt easy. The science continues to develop and the industry dynamics keep changing, so its tough for incumbents to figure out whether theyre making the right strategic choices, as we pointed out in arecent article. Theycant rely solely on traditional buying and selling relationships in the nascent syn-bio ecosystem; companies have to embark on co-development strategies, which help them make the right technology choices; choose the right partners; and use the right collaboration models.

Incumbents can use differenttypes of collaborations to enter the syn-bio industry: They can form or join focused consortiums; enter into joint ventures; or acquire, and merge with, syn-bio firms. As the Lesaffre case demonstrates, these strategies will evolve over time. In order to design successful collaborations, companies must take four steps.

The best starting points for formulating a syn-bio strategy are the most important challenges any incumbent faces today. Business is looking to make its processes less dependent on carbon-based energy sources; overcome the trade-offs between raw material costs and sustainability; create products with superior performance; and build resilient supply chainsall of which syn-bio can help with.

Consider, for instance, theLOral for the future program, which puts syn-bio at the heart of LOrals efforts to reach its 2030 sustainability targets. Committing itself to developing sustainable processes and producing green ingredients, LOral has turned tosyn-bio as one of theprograms three pillarsalong with green chemistry and green extraction. LOrealsOpen Innovation platform, which is catalyzing joint R&D projects, and its alliancessuch as the one with the French microalgae startup, Microphyttestify to its belief that syn-bio will resolve the tradeoffs between sustainability and profitability.

Onceincumbents have identified their most critical challenges, they must locate the assets and capabilities they will need to tackle them. Some they may already possess, as we have shownin a previousFortunearticle;others they will need to procure from the outside.

To do that, incumbentsshould consider forming, or becoming part of, focused consortiums or ecosystems that possess specific capabilities, or can provide access to specialized assets. CEOs can use achecklist to assess the capabilities they need and identify the firms with which they can form consortiums. They must ask:

* Do we need research, design, development, and intellectual property partners, such as startups that have capable R&D teams?

* Do we need sourcing partners, such as companies familiar with creating supply chains for novel feedstocks?

* Do we need manufacturing partners, such as syn-bio contract manufacturers familiar with precision fermentation and engineering?

Consider, for example, Germanys BASF, the worlds largest chemicals manufacturer, which hasinvested in LanzaTech, a Chicago-based syn-bio startup, to complement its technologies. In most industrial processes, exhaust gases are either flared or recovered to produce electricity and steam; LanzaTech has developed a microbe-based technology that uses those residual gases, which contain carbon monoxide and hydrogen, as feedstock to produce bioethanol.The partnership allows BASF and LanzaTechto help reduce the carbon emissions of many manufacturers, such as steel producers.

Most syn-bio consortiums are limited in scope, drawing on existing industry stacks, but joint ventures between incumbents and syn-bio firms offer more opportunities. They allow an incumbent the freedom to design a range of applications that fit its product portfolio; license the co-developed intellectual property; and exercise control over its strategies as syn-bio technologies mature. Thats critical, especially if theres a possibility that the technology could turn into the incumbents main driver of innovation tomorrow.

Winning with joint ventures is a challenge, though, and requires capabilities, capital, time, and talent. Last June, for instance, Unilever, which has created deep global capabilities in managing joint ventures, announced that it would strike a$120 million partnership with Geno(the erstwhile Genomatica). The incumbent and the startup are working to scale plant-based alternatives to palm oil as well as all the fossil fuel-based ingredients in Unilevers cleaning and personal care products. Not only is the joint venture targeting a large and diverse market, but the syn-bio substitutescould become Unilevers unique selling proposition in a range of product categories. Thatswhy the two companies decided that a joint venture would be the best mechanism to gain an edge over rivals.

A strategy of acquiring and integrating syn-bio startups is an effective way to augment incumbents capabilities, as the examples weve discussed show. It speeds up learning and capability development, enabling the organization to become more syn-bio-centric. By engaging with startups, incumbents are forced to become more agile and generate novel synergies among their teams and leaders.

For instance, Sanofi, theFrench pharmaceuticals giant, has been pursuing an M&A strategy in recent times, acquiring a number of cell and gene therapy startups in its focus areas such ashemophilia, immunology, oncology, rare diseases, and vaccines.In 2021 alone, Sanofimade key acquisitions of firms includingAmunix,Kadmon,Kladis,Kymab,Origimm,Tidal Therapeutics, andTranslate Biotakingits M&A investments since 2018 to over $30 billion.

At the same time, incumbents would do well to come to grips with scale of their ambitions. Those looking to lead in the industry may prefer to create syn-bio stacks and build a variety of applications. That strategy can be time- and investment-intensive, though: Building a bio-foundry alone will cost over $150 million, according to recent estimates, and maintenance expenses will add around 15% of that every year.Moreover, it will require incumbents to engage with a number of academic and research institutions, accelerators, and incubators in order to stay at the cutting edge. So, the ability to scale and diversify must be builtab initiointo any decision to build a syn-bio stack.

Industrial incumbents must keep in mind their experience with digital technologies. They thought they would never be affected by the resulting changes and, even if they were, that they could build out the IT capabilities they possessed. Soon, many realized that they lacked the talent and the technologies to take on digital upstarts, which forced them to acquire startups and work with digital giants. In the same way, if incumbents dont want to be disrupted for the second time in two decades, they would do well to come to grips with syn-bio by teaming up with syn-bio startupsright away.

ReadotherFortunecolumns by Franois Candelon.

Franois Candelon is a managing director and senior partner at BCG, and the global director of the BCG Henderson Institute.

Nicolas Goeldel is a project leader at BCG X Deep Tech and one of the firms synthetic biology experts.

Max Mnnig is a project leader at BCG and an ambassador at the BCG Henderson Institute.

Some of the companies featured in this column are current or past clients of BCG.

Visit link:

Synthetic biology could disrupt some of the worlds biggest industries. Here are four steps to building a syn-bio strategy - Fortune